The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Bradford Crutchfield net worth and biography

Bradford Crutchfield Biography and Net Worth

Insider of 10x Genomics

Brad Crutchfield has served as the Chief Commercial Officer of 10x Genomics since 2017, bringing more than 30 years of experience in commercial sales and marketing leadership to the company. Prior to joining 10x Genomics, he was QIAGEN’s Senior Vice President, life sciences business area, expanding the company’s global presence in the academic, pharmaceutical, and applied testing industries. Brad also served as Vice President and General Manager, Europe, Middle East & Africa for Illumina, and held positions of increasing responsibility with Bio-Rad Laboratories rising to Executive Vice President and President of the Life Science Group. He has also served as a director for Nanostring Technologies. Brad earned a B.S. in Physiology from the University of California, Davis.

What is Bradford Crutchfield's net worth?: The estimated net worth of Bradford Crutchfield is at least $1.66 million as of September 13th, 2021. Mr. Crutchfield owns 60,336 shares of 10x Genomics stock worth more than $1,664,670 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Crutchfield may own. Learn More about Bradford Crutchfield's net worth.
How do I contact Bradford Crutchfield?: The corporate mailing address for Mr. Crutchfield and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on Bradford Crutchfield's contact information.
Has Bradford Crutchfield been buying or selling shares of 10x Genomics?: Bradford Crutchfield has not been actively trading shares of 10x Genomics during the past quarter. Most recently, Bradford Crutchfield sold 17,000 shares of the business's stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $95.13, for a transaction totalling $1,617,210.00. Learn More on Bradford Crutchfield's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, insiders at the sold shares 29 times. They sold a total of 182,020 shares worth more than $9,613,552.06. The most recent insider tranaction occured on March, 4th when CEO Serge Saxonov sold 4,660 shares worth more than $205,040.00. Insiders at 10x Genomics own 10.7% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 3/4/2024.

Bradford Crutchfield Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2022	Sell	17,000	$95.13	$1,617,210.00
1/12/2022	Sell	17,000	$119.00	$2,023,000.00
12/13/2021	Sell	17,000	$139.36	$2,369,120.00
11/12/2021	Sell	17,000	$164.92	$2,803,640.00
10/12/2021	Sell	17,000	$157.30	$2,674,100.00
9/13/2021	Sell	17,000	$174.49	$2,966,330.00	60,336
7/12/2021	Sell	17,000	$186.53	$3,171,010.00
6/14/2021	Sell	17,000	$191.69	$3,258,730.00	60,262
5/12/2021	Sell	17,000	$134.78	$2,291,260.00	51,608
4/12/2021	Sell	17,000	$185.89	$3,160,130.00	51,608

Bradford Crutchfield Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $27.59

$26.62

$27.94

50 Day Range

MA: $37.70

$26.90

$48.45

2 Week Range

Now: $27.59

$26.30

$63.57

Volume

1,337,623 shs

Average Volume

1,473,041 shs

Market Capitalization

$3.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Move Your Money Before May 22

From Stansberry Research | Ad